Tesla Weighs China Business Separation Amid SpaceX Merger Speculation 
Anthropic Reveals Claude AI Accessed Real Production Systems During Cybersecurity Tests 
Same sparkle, different story: how lab-grown diamonds are transforming the market 
Chipotle Q2 Earnings Beat Expectations as Sales Growth Drives Higher 2026 Outlook 
Sony Raises Full-Year Outlook After Q1 Profit Jumps 40% on Gaming and Chip Growth 
Starbucks Stock Jumps as Q3 Earnings Beat, Sales Growth Drives Higher 2026 Outlook 
Amazon Q2 Earnings Beat Estimates as AWS AI Growth Surges, But Q3 Revenue Forecast Disappoints 
Holcim Raises 2026 Outlook After Strong Q2 Earnings Beat 
SpaceX Wins $1.6 Billion U.S. Space Force Launch Contracts for Falcon 9 Missions Through 2027 
Russia Charges Telegram Founder Pavel Durov With Facilitating Terrorism, Seeks International Arrest 
Toyota First-Half Global Sales and Production Decline on Weak China Demand, RAV4 Transition 
Microsoft Stock Jumps as Azure Growth, AI Revenue Beat Expectations 
Arm Holdings Q1 Earnings Beat Estimates, Strong Q2 Outlook Fails to Lift ARM Stock 
GSK Unveils $2.52 Billion Cost-Cutting Plan to Accelerate Drug Pipeline 
Qualcomm Stock Falls as Weak Q4 Forecast, Apple Revenue Decline Overshadow AI Data Center Growth 
World game at war: why some European nations have threatened a World Cup boycott 
Meta Stock Drops After Earnings Miss as AI Spending and Legal Costs Weigh on Profit 
SAN DIEGO, May 03, 2018 -- Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced today that the Company will host a conference call and live audio webcast on Thursday, May 10, 2018 at 5:00 p.m. ET to report its first quarter 2018 financial results and provide a corporate update.
In order to participate in the conference call, please dial 877-303-6235 (domestic) or 631-291-4837 (international) and refer to conference ID 5592629. The live webcast can be accessed under "Events & Presentations" in the Investors and Media section of the Company's website at www.fatetherapeutics.com. The archived webcast will be available on the Company's website beginning approximately two hours after the event.
About Fate Therapeutics, Inc.
Fate Therapeutics is a clinical-stage biopharmaceutical company engaged in the development of programmed cellular immunotherapies for cancer and immune disorders. The Company's hematopoietic cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf product candidates derived from engineered induced pluripotent cell lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients undergoing hematopoietic cell transplantation and to promote immune tolerance in patients with autoimmune disease. Fate Therapeutics is headquartered in San Diego, CA.
Contact:
Christina Tartaglia
Stern Investor Relations, Inc.
212.362.1200
[email protected]
